AI copilot for doctors that synthesizes peer-reviewed medical evidence at the point of care
Healthcare📍 Miami, FLFounded 2021
Current Valuation
$12B
as of 2026-Q1
DECACORN
IPO Outlookprivate
Is OpenEvidence going public?
No. OpenEvidence is private and has not filed to go public. There is no S-1 on file.
What is OpenEvidence's valuation in 2026?
OpenEvidence is valued at $12B as of 2026-Q1, set by its Series D ($250M, Jan 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has OpenEvidence filed an S-1?
No public S-1 is on file for OpenEvidence.
Who are OpenEvidence's investors?
OpenEvidence's investors include Thrive Capital, DST Global, Sequoia Capital, Kleiner Perkins, Coatue, Google Ventures.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
OpenEvidence is a Miami-based clinical AI company often called the 'ChatGPT for doctors' — its copilot synthesizes peer-reviewed medical literature into instantaneous, citation-backed answers at the point of care. Founded in 2021 by Kensho founder Daniel Nadler, it closed a $250M Series D in January 2026 co-led by Thrive Capital and DST Global at a $12B valuation, doubling from $6B six months earlier. Sacra estimates 2025 revenue at $150M, up over 1,800% YoY, with widespread adoption among U.S. physicians.
Company Profile
CEO
Daniel Nadler
Founded
2021
HQ
Miami, FL
Employees
~80
Total Raised
$700M
Est. Revenue
$150M (2025)
Growth
+1,803% YoY revenue growth (Sacra)
Last Round
Series D — $250M (Jan 2026) · Lead: Thrive Capital / DST Global (co-led)
IPO Status
private
Fundraising Status
Series D · $250M · 7 mo ago
privateTotal raised $700M
Secondary Market
Implied price / share
$454.21
Last round price / share
$487.38
vs last round
-6.8%
Open interest
14
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$250M
Jan 2026
Thrive Capital / DST Global (co-led)
—
Vertical Intelligence — AI / ML
Open models
0
Downloads (30d)
0
across all models
Followers
25
Attributed to Hugging Face organization "OpenEvidence" as of 2026-08-19. Open-weights footprint only — closed-model usage is not publicly measurable. Verify on Hugging Face ↗
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
7
via ashby
Product-build share
86%
engineering, research, product, design
Trajectory
steady
heavy product build — 86% of open roles are product-building functions (engineering/research/product) — 2 of 7 open roles are engineering.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Software Engineer, Data PlatformSoftware Engineer, Backend and InfrastructureSecurity Engineer, Platform Security Software Engineer, Site ReliabilityResearch ScientistSoftware Engineer, Applied AI
Counted from OpenEvidence's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Daniel NadlerZachary Ziegler
Investors
Thrive Capital · DST Global · Sequoia Capital · Kleiner Perkins · Coatue · Google Ventures
Products
OpenEvidence Clinical AI Copilot
Point-of-Care Evidence Search
Specialty-Specific Knowledge Graphs
EHR-Integrated Decision Support
Competitors
UpToDate (Wolters Kluwer) · DynaMed · Hippocratic AI · Abridge · Glass Health
AIHealthcareClinical Decision SupportDecacornMedical AI
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q1. Refreshed quarterly.